Who Paid My Doc
Elizabeth Kirshner
Nurse Practitioner Ann Arbor, MI Nurse Practitioner
NPI 1902061872 CMS profile 11003239
1211 Hogback Rd, Ann Arbor, MI 48105
General payments
$172
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$118,450
Through program year 2021, Elizabeth Kirshner of Ann Arbor, MI is reported in the CMS Open Payments database as having received $172 across 3 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $118,450 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 36th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $172 | 3 |
Beside peers
- Elizabeth Kirshner
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Elizabeth Kirshner were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Elizabeth Kirshner | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $172 | $135 | $40–$426 | $132 |
| 2022 | $0 | $152 | $48–$470 | $149 |
| 2023 | $0 | $166 | $54–$529 | $160 |
| 2024 | $0 | $173 | $55–$556 | $164 |
| 2025 | $0 | $174 | $55–$557 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
3,099
Drug cost
$315,566
Branded share of claims
71.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 1,814 | $201,755 | |
| Buprenorphine | Generic | 136 | $33,659 | |
| Suboxone Buprenorphine Hcl/Naloxone Hcl | Brand | 54 | $21,798 | |
| Belbuca Buprenorphine Hcl | Brand | 23 | $20,641 | |
| Zubsolv Buprenorphine Hcl/Naloxone Hcl | Brand | 44 | $17,137 | |
| Buprenorphine Hcl | Generic | 215 | $8,384 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 191 | $3,921 | |
| Varenicline Tartrate | Generic | 12 | $2,695 | |
| Gabapentin | Generic | 160 | $1,860 | |
| Fentanyl | Generic | 15 | $774 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner in Michigan
Related records
Nurse Practitioner in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.